MAM
JK Technosoft Ltd appoints Chhavi Sood as marketing head
MUMBAI: Ms. Chhavi Sood has been appointed as Marketing Head at JK Technosoft Ltd., a global software solutions provider enabling businesses to make informed decisions with data driven analytics. Her amassed expertise lies in Corporate Communications and PR, Digital Marketing, Analyst Relations, Market Research, Brand Management along with Sales & Business Development and lead generation across IT and Mobile & VAS sector.
An experienced professional with over 14 years of experience, Ms. Chhavi’s last assignment as Senior Marketing Manager at iSON Technologies involved driving communications and marketing initiatives across Africa and Middle East region.
An alumnus of Symbiosis Institute of Management Studies, she did her MBA in Telecom Management & IT. She also holds a degree in Electronic Engineering from University of Pune. During her remarkable career spanning 14 years she has worked with companies like Altran (erstwhile Aricent Group), Cap Gemini (erstwhile Patni Computers) and IMI mobile across the US, UK, BENELUX and LATAM regions. Her valuable knowledge in strategic marketing and the importance of building strong and lasting business relationships will be valuable in helping JK Technosoft in expanding market share in US and UK market.
Commenting on her new role as Marketing Head, Ms. Chhavi Sood said, "I'm delighted to join JK Technosoft family. JK Technosoft is a key player in digital transformation and the uniqueness lies in the qualified global talent pool. This gives us a competitive advantage and continued growth. I am confident that JK Technosoft is strongly positioned for newer heights."
Delighted on the joining of Ms. Chhavi Sood, Mr. Satish Gupta, Executive Director, JK Technosoft Ltd., said, “Chhavi is a seasoned professional who brings with years of experience in the marketing and communications field. We are pleased to welcome her at JK Technosoft to scale up our existing business.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
